Jafron Biomedical (300529) Fundamentals 2026 — P/E 24.3x, Revenue Analysis | SniperIQ
Jafron Biomedical (300529) is a CN-listed Healthcare company in Medical - Specialties with a market capitalization of ¥14.0B, trading at ¥17.55 on the SHZ. This SniperIQ fundamentals page covers Jafron Biomedical's valuation (P/E 24.3x, P/B 3.7x), profitability (net margin 27.9%), revenue (¥2.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Jafron Biomedical's market cap?
Jafron Biomedical (300529) has a market capitalization of approximately ¥14.0B, trading at ¥17.55 on the SHZ. Market cap moves with the live share price.
What is Jafron Biomedical's P/E ratio?
Jafron Biomedical's trailing twelve-month P/E ratio is 24.3x, with a price-to-book (P/B) of 3.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Jafron Biomedical?
Jafron Biomedical runs a net profit margin of 27.9%, a gross margin of 76.9%, and an operating margin of 35.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Jafron Biomedical generate?
Jafron Biomedical reported revenue of ¥2.0B for fiscal year 2025, with net income of ¥533M and earnings per share (EPS) of 0.69. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Jafron Biomedical pay a dividend?
Jafron Biomedical offers a trailing dividend yield of about 3.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Jafron Biomedical financially healthy?
Jafron Biomedical carries a debt-to-equity ratio of 0.34x and a current ratio of 8.71x, with a market beta of 0.44. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Jafron Biomedical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Jafron Biomedical (300529) the key facts are: market cap ¥14.0B, P/E 24.3x, revenue ¥2.0B, 52-week range 14.73-24.98. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Jafron Biomedical's full fundamentals live
Get Jafron Biomedical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.